灵芝三萜类化合物干预对葡聚糖硫酸钠诱导小鼠炎症性肠病的预防作用研究

黄茹菲; HUANG Rufei; 夏欢; XIA Huan; 王朝阳; WANG Zhaoyang; 钟小兰; ZHONG Xiaolan

doi:10.48014/atcm.20251110002

灵芝三萜类化合物干预对葡聚糖硫酸钠诱导小鼠炎症性肠病的预防作用研究

Study on Preventive Effects of Ganoderma Lucidum Triterpenoids Intervention on Dextran Sulfate Sodium-induced Inflammatory Bowel Disease in Mice

中医药研究进展 2026年第2卷第2期页码[16-22] 下载全文[2.4MB]

摘要

炎症性肠病 (IBD) 涉及肠道屏障功能障碍、免疫失调和肠道菌群失衡。灵芝三萜 (GLT) 显示出抗炎潜力, 但其对IBD 是否具有治疗作用仍不清楚。为此, 本研究利用3%的葡聚糖硫酸钠 (DSS) 建立IBD模型小鼠并进行GLT灌胃 (20mg/kg) 治疗, 通过记录小鼠体重、结肠长度与疾病活动指数 (DAI) , 并利用免疫组化检测黏膜糖蛋白Muc2与屏障相关蛋白ZO-1/Occludin的表达变化, 从而综合评价GLT对IBD症状的预防性干预效果。结果显示, 与DSS模型组相比, GLT显著降低DAI, 减轻体重下降并改善结肠缩短, 结肠组织学损伤明显减轻。此外, GLT恢复了杯状细胞数量并提高Muc2表达, 同时上调ZO-1和Occludin的表达。这些发现表明, GLT 通过增强上皮紧密连接与黏液分泌, 改善肠道屏障功能, 从而缓解DSS诱导的结肠炎, 提示其具有作为炎症性肠病干预候选物的潜在价值。

Abstract

Inflammatory bowel disease (IBD) involves intestinal barrier dysfunction, immune dysregulation, and gut microbiota imbalance. Ganoderma lucidum triterpenoids (GLT) have shown anti-inflammatory potential, but the therapeutic effect on IBD remains unclear. Therefore, In this study, a mouse model of inflammatory bowel disease (IBD) was established using 3% dextran sulfate sodium (DSS) , and the modeled mice were treated with GLT via intragastric administration at a dosage of 20 mg/kg. The body weight and colon length of mice were recorded, and the disease activity index (DAI) was evaluated. Immunohistochemistry was performed to detect the expression changes of mucosal glycoprotein Muc2 and barrier-associated proteins ZO- 1 and Occludin. Based on the above experimental results, the preventive intervention effect of GLT on IBD symptoms was comprehensively assessed. The results showed that compared with the DSS model group, GLT significantly reduced the DAI score, alleviated body weight loss, and ameliorated colon shortening; histological injury of colonic tissue was markedly attenuated. Furthermore, GLT restored the number of goblet cells and increased Muc2 expression, while upregulating the expression of ZO-1 and Occludin. These findings indicate that GLT improved intestinal barrier function by enhancing epithelial tight junctions and mucus secretion, thereby alleviating DSS-induced colitis. It suggests that GLT has potential value as a candidate intervention for inflammatory bowel disease.

DOI

10.48014/atcm.20251110002

文章类型

研究性论文

收稿日期

2025-11-10

接收日期

2025-12-31

出版日期

2026-06-28

关键词

灵芝, 三萜类化合物, 炎症性肠病, 肠道屏障功能

Keywords

Ganoderma lucidum, triterpenoids, inflammatory bowel disease, intestinal barrier function

作者

黄茹菲^1,2,3,*, 夏欢⁴, 王朝阳^2,3, 钟小兰^2,3,*

Author

HUANG Rufei^1,2,3,*, XIA Huan⁴, WANG Zhaoyang^2,3, ZHONG Xiaolan^2,3,*

所在单位

1. 暨南大学附属第一医院, 广州 510632
2. 广州市花都医学研究所, 广州 510800
3. 广州市花都区人民医院, 广州 510800
4. 暨南大学生命科学技术学院, 广州 510632

Company

1. The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
2. Huadu Institute of Medicine, Guangzhou 510800, China
3. Huadu District People’s Hospital of Guangzhou, Guangzhou 510800, China
4. College of Life Science and Technology, Jinan University, Guangzhou 510632, China

浏览量

111

下载量

120

基金项目

广州市医学重点学科(2025—2027年)

参考文献

[1] 李涛, 姜敏, 孙铭璐, 等. 炎症性肠病的病理分型、发病机制与膳食干预策略研究进展[J]. 食品工业科技, 2026, 47(12): 485-496.
https://doi.org/10.13386/j.issn1002-0306.2025060077.
[2] 周宇, 关红, 高莉莉, 等. 炎症性肠病病人生活质量的研究进展[J]. 护理研究, 2020, 34(02): 264-268.
https://doi.org/10.12102/j.issn.1009-6493.2020.02.016.
[3] Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies[J]. J Crohns Colitis, 2024, 18(Supplement_2): ii3-ii15.
https://doi.org/10.1093/ecco-jcc/jjae082.
[4] Hracs L, Windsor J W, Gorospe J, et al. Global evolution of inflammatory bowel disease across epidemiologic stages[J]. Nature, 2025, 642(8067): 458-466.
https://doi.org/10.1038/s41586-025-08940-0.
[5] Li F, Wang X, Cai Y, et al. Gut microbiota-derived metabolites and their interactions with host: A new potential key point in the pathogenesis and treatment of inflammatory bowel disease[J]. Fundamental Research, 2025, 5(6): 2622-2625.
https://doi.org/10.1016/j.fmre.2024.01.018.
[6] Little R D, Jayawardana T, Koentgen S, et al. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions[J]. eGastroenterology, 2024, 2(1): e100006.
https://doi.org/10.1136/egastro-2023-100006.
[7] 郭昭, 庄浩岩, 史学文. 炎症性肠病潜在的治疗方法及其作用机制研究进展[J]. 胃肠病学和肝病学杂志, 2025, 34(04): 590-594.
https://cjournal.hep.com.cn/1006-5709/CN/1159974436582645922.
[8] Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment[J]. J Crohns Colitis, 2022, 16(1): 2-17.
https://doi.org/10.1093/ecco-jcc/jjab178.
[9] Chanchlani N, Lin S, Bewshea C, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study[J]. The Lancet Gastroenterology & Hepatology, 2024, 9(6): 521-538.
https://doi.org/10.1016/S2468-1253(24)00044-X.
[10] Liu Y, Li B G, Su Y H, et al. Potential activity of Traditional Chinese Medicine against Ulcerative colitis: A review[J]. Journal of Ethnopharmacology, 2022, 289(1): 115084.
https://doi.org/10.1016/j.jep.2022.115084.
[11] 孟欢, 侯晓婷, 张华敏, 等. 中药天然产物治疗炎症性肠病的研究进展[J]. 中草药, 2023, 54(10): 3349-3369.
https://doi.org/10.7501/j.issn.0253-2670.2023.10.032.
[12] Sarkar T, Mazumder B, Nandi G, et al. Reishi Mushroom( Ganoderma lucidum): pharmacology of a potent healer in traditional Chinese medicine[J]. Nat Prod Res, 2025: 1-18.
https://doi.org/10.1080/14786419.2025.2511162.
[13] Ahmad R, Riaz M, Khan A, et al. Ganoderma lucidum(Reishi)an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties[J]. Phytother Res, 2021, 35(11): 6030-6062.
https://doi.org/10.1002/ptr.7215.
[14] Xia Q, Zhang H, Sun X, et al. A comprehensive review of the structure elucidation and biological activity of triterpenoids from Ganoderma spp[J]. Molecules, 2014, 19(11): 17478-17535.
https://doi.org/10.3390/molecules191117478.
[15] Wu Y L, Han F, Luan S S, et al. Triterpenoids from Ganoderma lucidum and Their Potential Anti-inflammatory Effects[J]. J Agric Food Chem, 2019, 67(18): 5147-5158.
https://doi.org/10.1021/acs.jafc.9b01195.
[16] Neurath M F, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer[J]. Lancet Gastroenterol Hepatol, 2025, 10(6): 573-592.
https://doi.org/10.1016/s2468-1253(24)00390-x.
[17] Günzel D, Yu A S. Claudins and the modulation of tight junction permeability[J]. Physiol Rev, 2013, 93(2): 525-569.
https://doi.org/10.1152/physrev.00019.2012.
[18] Kuo W T, Odenwald M A, Turner J R, et al. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival[J]. Ann N Y Acad Sci, 2022, 1514(1): 21-33.
https://doi.org/10.1111/nyas.14798.
[19] Al-Sadi R, Khatib K, Guo S, et al. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 300(6): G1054-1064.
https://doi.org/10.1152/ajpgi.00055.2011.
[20] Ye Y, Abulizi A, Zhang Y, et al. Ganoderic Acid Ameliorates Ulcerative Colitis by Improving Intestinal Barrier Function via Gut Microbiota Modulation[J]. Int J Mol Sci, 2025, 26(6): 2466.
https://doi.org/10.3390/ijms26062466.
[21] Liu C, Dunkin D, Lai J, et al. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-κB Signaling[J]. Inflamm Bowel Dis, 2015, 21(8): 1918-1925.
https://doi.org/10.1097/mib.0000000000000439.

引用本文

黄茹菲, 夏欢, 王朝阳, 等. 灵芝三萜类化合物干预对葡聚糖硫酸钠诱导小鼠炎症性肠病的预防作用研究[J]. 中医药研究进展, 2026, 2(2): 16-22.

Citation

HUANG Rufei, XIA Huan, WANG Zhaoyang, et al. Study on Preventive Effects of Ganoderma Lucidum Triterpenoids Intervention on Dextran Sulfate Sodium-induced Inflammatory Bowel Disease in Mice[J]. Advances in Traditional Chinese Medicine, 2026, 2(2): 16-22.